IL293623A - Treatment of acute myeloid leukemia or myelodysplastic syndrome - Google Patents
Treatment of acute myeloid leukemia or myelodysplastic syndromeInfo
- Publication number
- IL293623A IL293623A IL293623A IL29362322A IL293623A IL 293623 A IL293623 A IL 293623A IL 293623 A IL293623 A IL 293623A IL 29362322 A IL29362322 A IL 29362322A IL 293623 A IL293623 A IL 293623A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- dose
- patients
- aml
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944876P | 2019-12-06 | 2019-12-06 | |
| PCT/CA2020/051668 WO2021108918A1 (en) | 2019-12-06 | 2020-12-04 | Treatment for acute myeloid leukemia or myelodysplastic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL293623A true IL293623A (en) | 2022-08-01 |
Family
ID=76221282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL293623A IL293623A (en) | 2019-12-06 | 2020-12-04 | Treatment of acute myeloid leukemia or myelodysplastic syndrome |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12533357B2 (https=) |
| EP (1) | EP4069246A4 (https=) |
| JP (1) | JP2023505301A (https=) |
| KR (1) | KR20220124177A (https=) |
| CN (1) | CN115397429A (https=) |
| AU (1) | AU2020396807A1 (https=) |
| BR (1) | BR112022011052A2 (https=) |
| CA (1) | CA3163796A1 (https=) |
| IL (1) | IL293623A (https=) |
| MX (1) | MX2022006910A (https=) |
| TW (1) | TWI880995B (https=) |
| WO (1) | WO2021108918A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| JP7717842B2 (ja) | 2021-05-11 | 2025-08-04 | オリック ファーマシューティカルズ，インク． | ポロ様キナーゼ４阻害剤 |
| US20250049787A1 (en) * | 2021-12-22 | 2025-02-13 | University Health Network | Treatment for acute myeloid leukemia or lymphoma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2465971T3 (es) | 2009-04-06 | 2014-06-09 | University Health Network | Inhibidores de quinasa y método para tratar cáncer con los mismos |
| SI2556071T1 (sl) * | 2010-04-06 | 2016-12-30 | University Health Network | Kinazni inhibitorji in njihova uporaba pri zdravljenju raka |
| ES2706066T3 (es) * | 2010-07-02 | 2019-03-27 | Univ Health Network | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| WO2015051304A1 (en) | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions, biomarkers and their use in treatment of cancer |
| HUE043194T2 (hu) * | 2013-10-18 | 2019-08-28 | Univ Health Network | PLK-4 inhibitor sója és kristályformái |
| US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| JP6617208B2 (ja) | 2017-03-31 | 2019-12-11 | ノバルティス アーゲー | 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン |
| WO2019046949A1 (en) * | 2017-09-08 | 2019-03-14 | University Health Network | POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE |
| EP3720560A4 (en) * | 2017-12-06 | 2022-01-05 | Ludwig Institute for Cancer Research Ltd | METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS |
-
2020
- 2020-12-04 BR BR112022011052A patent/BR112022011052A2/pt unknown
- 2020-12-04 US US17/782,632 patent/US12533357B2/en active Active
- 2020-12-04 AU AU2020396807A patent/AU2020396807A1/en active Pending
- 2020-12-04 KR KR1020227023046A patent/KR20220124177A/ko active Pending
- 2020-12-04 TW TW109142965A patent/TWI880995B/zh active
- 2020-12-04 CN CN202080095784.4A patent/CN115397429A/zh active Pending
- 2020-12-04 IL IL293623A patent/IL293623A/en unknown
- 2020-12-04 EP EP20895810.8A patent/EP4069246A4/en active Pending
- 2020-12-04 CA CA3163796A patent/CA3163796A1/en active Pending
- 2020-12-04 MX MX2022006910A patent/MX2022006910A/es unknown
- 2020-12-04 WO PCT/CA2020/051668 patent/WO2021108918A1/en not_active Ceased
- 2020-12-04 JP JP2022534233A patent/JP2023505301A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115397429A (zh) | 2022-11-25 |
| US12533357B2 (en) | 2026-01-27 |
| WO2021108918A1 (en) | 2021-06-10 |
| AU2020396807A1 (en) | 2022-07-21 |
| CA3163796A1 (en) | 2021-06-10 |
| MX2022006910A (es) | 2022-11-09 |
| TWI880995B (zh) | 2025-04-21 |
| KR20220124177A (ko) | 2022-09-13 |
| BR112022011052A2 (pt) | 2022-08-16 |
| EP4069246A4 (en) | 2023-12-06 |
| EP4069246A1 (en) | 2022-10-12 |
| TW202134237A (zh) | 2021-09-16 |
| JP2023505301A (ja) | 2023-02-08 |
| US20230010772A1 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12533357B2 (en) | Treatment for acute myeloid leukemia or myelodysplastic syndrome | |
| US20120295864A1 (en) | Method for treating acute myeloid leukemia | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP7266030B2 (ja) | リンパ球悪性疾患を治療するための方法 | |
| AU2012321110A1 (en) | Combination treatment | |
| JP7611855B2 (ja) | ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩 | |
| WO2015006822A1 (en) | Method of pre-preparing medications for therapeutic uses | |
| JP2023109899A (ja) | 少なくとも１つのスプライソソームモジュレーターと、ｂｃｌ２阻害剤、ｂｃｌ２／ｂｃｌｘｌ阻害剤及びｂｃｌｘｌ阻害剤から選択される少なくとも１つの阻害剤とを含む組合せ、並びに使用の方法 | |
| CN113329749B (zh) | 用于治疗葡萄膜黑色素瘤的联合疗法 | |
| US20230132982A1 (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
| TWI849001B (zh) | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 | |
| CN113509475A (zh) | Bcl-2/bcl-xl抑制剂的组合及相关用途 | |
| CA3245251A1 (en) | TREATMENT METHOD COMPRISING KRAS G12C INHIBITORS AND SHP2 INHIBITORS | |
| EA049792B1 (ru) | Лечение острого миелоидного лейкоза или миелодиспластического синдрома | |
| US20240335440A1 (en) | Combination therapy comprising a pkc inhibitor and a c-met inhibitor | |
| JP2026510567A (ja) | 血液悪性腫瘍の治療におけるロギノリシブ及びｂｃｌ－２阻害剤の組み合わせ |